BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
NEMLUVIO (nemolizumab-ilto) by Galderma is interleukin-31 receptor alpha antagonists [moa]. First approved in 2024.
Drug data last refreshed 16m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEMLUVIO (nemolizumab-ilto) is a monoclonal antibody antagonist of interleukin-31 receptor alpha, a novel mechanism targeting pruritus and inflammatory skin disease. It is administered via subcutaneous injection and represents Galderma's entry into the IL-31 pathway space. The drug was approved by the FDA on August 12, 2024.
Growth
As a newly approved 2024 product in growth phase, the brand team is expected to scale rapidly with expanding field and commercial functions to capture market share in the emerging IL-31 antagonist category.
Mechanism of Action
Interleukin-31 Receptor alpha Antagonists
Pharmacologic Class:
Interleukin-31 Receptor alpha Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEMLUVIO represents a career-building opportunity at a product's inflection point—newly approved with significant commercial build ahead. Early adoption into a launch-phase biologic typically offers rapid advancement, visibility, and responsibility as the brand scales from launch into growth.
Brand Manager
Worked on NEMLUVIO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.